Idorsia’s JERAYGO (aprocitentan) Approved in Canada to Treat Resistant Hypertension

Idorsia Ltd (SIX: IDIA) announced that Health Canada has granted marketing authorization for **JERAYGO™ (aprocitentan)** to treat **resistant hypertension** in adults whose blood pressure remains uncontrolled despite using at least three different antihypertensive medications in combination. This approval marks JERAYGO as the *first and only endothelin receptor antagonist* available for this indication in Canada, offering a novel therapeutic option that targets a previously unaddressed biological pathway. The prescribed starting dose is 12.5 mg once daily by mouth, with the option to increase to 25 mg daily for patients who tolerate the lower dosage but need tighter blood pressure control. Resistant hypertension affects about 10 % of people with high blood pressure, highlighting the urgent need for improved treatments. Aprocitentan is a dual endothelin receptor antagonist that blocks the binding of endothelin‑1 to its receptors ETₐ and ETᵦ, helping relax blood vessels and lower blood pressure. It is already approved in other major regions — including the U.S., EU, UK, and Switzerland — and represents the first systemic antihypertensive to exploit this new pathway in more than three decades. #ResistantHypertension #JERAYGO #Idorsia #HealthCanada #SlimScan #GrowthStocks #CANSLIM